Dana Biotechnology was founded in March 2014 and is a Chinese enterprise specializing in the development, production, and sales of innovative in vitro diagnostic products for invasive fungal diseases and other pathogenic microorganisms. It has been selected as one of the first batch of national key specialized, refined, and innovative "little giant" enterprises, a national intellectual property advantage enterprise, and a single champion enterprise in Tianjin's manufacturing industry. The company currently has over 330 employees and has established Tianjin Enterprise Technology Center, Tianjin Enterprise Key Laboratory, Academician Expert Workstation, and Postdoctoral Workstation. Hosted over 20 major national and Tianjin science and technology projects, obtained 72 national authorized patents, and obtained 70 medical device registration certificates. For the first time, a 5G+fungal combined detection protocol was proposed and established, providing accurate diagnostic evidence for the treatment of invasive fungal diseases, significantly reducing mortality and improving cure rates. The company's core products have entered more than 1300 benchmark medical institutions and independent third-party medical testing laboratories nationwide, and have been clinically applied in key hospitals in more than 100 countries overseas, receiving unanimous praise in clinical testing. It has won the first prize for military scientific and technological progress, the second prize for Tianjin scientific and technological progress, the second prize for Tianjin scientific and technological progress (special prize for combating COVID-19), and the nomination prize for Tianjin Quality Award, and has become a global leader in the precise diagnosis of fungal diseases.

Please click download for job details: View available positions.xls